Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)

被引：75

作者：

Hidalgo, M

Bloedow, D

机构：

[1] Sidney Kimmel Canc Ctr, Baltimore, MD 21231 USA

[2] Genentech Inc, Dept Expt & Clin Pharmacol, San Francisco, CA 94080 USA

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 03期

关键词：

D O I：

10.1016/S0093-7754(03)00186-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：25 / 33

页数：9

共 26 条

[1]

Akita Robert W., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1003

[2] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].

Albanell, J ;

Rojo, F ;

Averbuch, S ;

Feyereislova, A ;

Mascaro, JM ;

Herbst, R ;

LoRusso, P ;

Rischin, D ;

Sauleda, S ;

Gee, J ;

Nicholson, RI ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124

[3]

Baselga J, 2000, J CLIN ONCOL, V18, p54S

[4] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[5] Changes in plasma protein binding have little clinical relevance [J].

Benet, LZ ;

Hoener, BA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121

[6]

FINKLER N, 2001, P AN M AM SOC CLIN, V20, pA208

[7]

FUKOUKA M, 2002, P AN M AM SOC CLIN, V21, pA298

[8] Pleural mesothelioma: combined modality treatments [J].

Giaccone, G .

ANNALS OF ONCOLOGY, 2002, 13 :217-225

[9] Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial [J].

Herbst, RS ;

Maddox, AM ;

Small, EJ ;

Rothenberg, L ;

Small, EL ;

Rubin, EH ;

Baselga, J ;

Rojo, F ;

Hong, WK ;

Swaisland, H ;

Averbuch, SD ;

Ochs, J ;

LoRusso, PM .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3815-3825

[10] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].

Hidalgo, M ;

Siu, LL ;

Nemunaitis, J ;

Rizzo, J ;

Hammond, LA ;

Takimoto, C ;

Eckhardt, SG ;

Tolcher, A ;

Britten, CD ;

Denis, L ;

Ferrante, K ;

Von Hoff, DD ;

Silberman, S ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279

← 1 2 3 →